Xenetic Biosciences (XBIO) AI Stock Analysis

• Market Cap: $5.22M
• Dividend Yield: N/A
• Average Volume (3M): 1.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: 13.30%
• EPS Growth: 22.70%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 2,291,056
• 10 Day Avg. Volume: 5,053,508
• 30 Day Avg. Volume: 1,695,238
• PEG Ratio: 0.30
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 0.44
• Enterprise Value/Gross Profit: 0.44
• Enterprise Value/Ebitda: -0.39
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $2.00 ▼(-9.50% Downside)

The score is held down primarily by persistent losses and negative free cash flow alongside a shrinking equity cushion, with weak technical trend and negative MACD reinforcing downside risk. Low/no debt and improving revenue provide some support, but valuation remains challenged due to lack of profitability, and the delayed annual meeting adds a modest governance overhang.

Positive Factors

Strategic R&D collaboration with Scripps

Extended collaboration with a top research institute provides durable scientific validation and access to external translational expertise. Positive preclinical signals in multiple tumor models can materially de-risk the program, improve IND-readiness odds, and attract future partners or co-development funding.

Top-line momentum

Consistent revenue growth, though from a small base, demonstrates emerging commercial or collaboration traction and reduces sole dependence on financing. Sustained top-line trends can lengthen runway, support incremental R&D spend, and signal market interest in the DNase platform to strategic partners.

Minimal leverage

A debt-free balance sheet lowers structural financial risk, preserving flexibility to fund development through equity or partnerships without interest burdens. For a pre-commercial biotech, this conservatism helps absorb long development timelines and supports strategic optionality for future capital raises or collaborations.

Negative Factors

Persistent negative cash flow

Ongoing negative operating and free cash flow means the company depends on external capital to sustain R&D and operations. This structural cash burn increases financing risk, can force dilution or program cutbacks, and constrains multi-year development planning unless cash generation turns positive.

Shrinking equity base increases dilution risk

A materially reduced equity cushion reflects cumulative losses and prior dilutive financings. That erosion heightens the probability of further equity raises to fund operations, which can dilute existing shareholders and limit the company’s ability to finance programs on non-dilutive terms long-term.

Governance and shareholder engagement issues

Repeated adjournments for lack of quorum signal weak shareholder engagement and governance frictions. This can delay board or strategy decisions, complicate timely approvals for financings or partnerships, and may reduce confidence among institutional partners and long-term investors.

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

How the Company Makes Money

Xenetic Biosciences makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves licensing its technologies to pharmaceutical partners, thereby earning milestone payments and royalties on the sales of drugs developed using its platforms. Xenetic also engages in collaborations and strategic partnerships to co-develop therapies, which may include upfront payments, research funding, and shared revenues from successful products. Additionally, the company may receive government grants and funding to support its research initiatives.

Xenetic Biosciences Financial Statement Overview

Summary

Xenetic Biosciences is facing significant profitability challenges, with negative net profit margins and ongoing operational inefficiencies. While the company maintains a strong equity ratio and zero debt, its negative cash flow and return on equity highlight struggles in generating positive returns for shareholders.

Income Statement

Xenetic Biosciences has shown inconsistent revenue growth, with the latest annual revenue decreasing slightly by 1.6%. The gross profit margin remains strong at 100%, indicating efficient cost management relative to revenue. However, the company faces significant challenges with profitability, as evidenced by a negative net profit margin of -158.4% and consistent EBIT and EBITDA losses, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 87%. The company has no debt, which minimizes financial risk and provides stability. However, the return on equity is negative due to ongoing net losses, highlighting challenges in generating shareholder returns.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash consumption in operations. The free cash flow also reflects a negative trend, although there is a slight improvement from the previous year. The cash flow to net income ratios are not favorable due to negative net income, suggesting struggles in translating operational activities into positive cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.86M	2.50M	2.54M	1.71M	1.16M	436.94K
Gross Profit	2.86M	2.50M	2.54M	1.71M	1.16M	436.94K
EBITDA	-3.29M	-4.05M	-4.52M	-6.69M	-5.71M	-4.67M
Net Income	-3.16M	-3.96M	-4.13M	-6.55M	-5.65M	-10.89M
Balance Sheet
Total Assets	5.07M	6.90M	10.61M	14.72M	19.82M	13.18M
Cash, Cash Equivalents and Short-Term Investments	4.12M	6.17M	8.98M	13.10M	18.24M	11.53M
Total Debt	0.00	0.00	0.00	0.00	27.04K	62.52K
Total Liabilities	1.11M	894.26K	809.59K	1.07M	1.42M	963.97K
Stockholders Equity	3.96M	6.01M	9.80M	13.65M	18.39M	12.22M
Cash Flow
Free Cash Flow	-2.72M	-2.82M	-4.11M	-5.15M	-4.74M	-4.27M
Operating Cash Flow	-2.72M	-2.82M	-4.11M	-4.65M	-4.74M	-4.27M
Investing Cash Flow	0.00	0.00	0.00	-500.00K	0.00	0.00
Financing Cash Flow	0.00	0.00	0.00	0.00	11.45M	5.43M

Xenetic Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.21
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Neutral. The current price of 2.21 is above the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.37, and below the 200-day MA of 3.07, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 56.70 is Neutral, neither overbought nor oversold. The STOCH value of 73.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XBIO.

Xenetic Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	49 Neutral	$18.87M	-0.72	-70.67%	―	6.29%	7.42%
APRE	43 Neutral	$6.25M	-0.42	-74.72%	―	-62.75%	23.87%
HCWB	43 Neutral	$3.74M	―	―	―	-87.93%	65.26%
XBIO	42 Neutral	$5.22M	-1.18	-57.43%	―	13.30%	22.70%

Xenetic Biosciences Corporate Events

Xenetic Biosciences faces ongoing delays in annual meeting

On December 11, 2025, Xenetic Biosciences, Inc. announced that its 2025 Annual Meeting of Stockholders, originally scheduled for that day, was adjourned until January 8, 2026 to achieve a quorum and allow more time to solicit proxies on behalf of the board. When the meeting reconvened on January 8, 2026, it was again adjourned without any business conducted due to the continued lack of a requisite quorum, and the company now plans to reconvene the meeting at a future, yet-to-be-determined date, signaling ongoing stockholder engagement and governance challenges that could delay corporate decision-making.

The most recent analyst rating on (XBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Xenetic Biosciences stock, see the XBIO Stock Forecast page.

Xenetic Biosciences Adjourns 2025 Annual Meeting

On December 11, 2025, Xenetic Biosciences announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum, with plans to reconvene on January 8, 2026. The adjournment allows additional time to solicit proxies, and stockholders who have not yet voted are encouraged to do so. The meeting will continue to be held virtually, and previously submitted votes remain valid unless revoked.